Despite a prolonged sell-off in biotech stocks, the development of genomic medicine has continued apace. For just the third time,…
McAlinden Research PartnersMay 23, 2022
A wealth of new data from several leading genomics firms have launched stocks in the sector higher in the fourth…
McAlinden Research PartnersDecember 22, 2020
New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…
McAlinden Research PartnersSeptember 1, 2020
Treatments utilizing Clustered Regularly Interspace Short Palindromic Repeats (CRISPR), continue to rack up clinical success. The latest research on blood…
McAlinden Research PartnersJune 16, 2020
Though many sectors have been whacked by the Coronavirus-related hurdles in 2020, research and development of the gene editing technology…
McAlinden Research PartnersMay 13, 2020
New research on CRISPR techniques that could provide treatments and improved diagnostics for several major viruses and other medical conditions…
McAlinden Research PartnersNovember 13, 2019
New developments in CRISPR gene editing technology have opened the door to potential cures for 89% of known disease-causing genetic…
McAlinden Research PartnersOctober 29, 2019
After some major hiccups last year, new breakthroughs suggest CRISPR is becoming a mainstay in healthcare. The technology is now…
McAlinden Research PartnersMay 28, 2019
Startups are experimenting with the gene-editing technology CRISPR to make lab-grown meat a commercially viable reality. Meanwhile, the first commercially…
McAlinden Research PartnersMarch 18, 2019
